Skip to main content
Equibles

Fred Hassan

Board Member

Cocrystal Pharma, Inc. (COCP)

Board Member

BridgeBio Pharma, Inc. (BBIO)

Board Member

EyePoint, Inc. (EYPT)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Fred Hassan

Fred Hassan is recorded as Board Member at Cocrystal Pharma, Inc. (COCP), Board Member at BridgeBio Pharma, Inc. (BBIO) and Board Member at EyePoint, Inc. (EYPT). EyePoint, Inc. reported in an 8-K filed September 4, 2024 that Fred Hassan was appointed Board of Directors, effective September 3, 2024. Cocrystal Pharma, Inc. reported in an 8-K filed April 24, 2023 that Fred Hassan was appointed director, effective April 20, 2023.

“the Board, upon the recommendation of the Governance and Nominating Committee of the Board (the "Governance and Nominating Committee"), reduced the size of the Board from nine to eight members and appointed Fred Hassan to fill the remaining vacancy on the Board.”
EyePoint, Inc. Form 8-K, filed September 4, 2024 · Read the filing
“On April 20, 2023, the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) appointed Fred Hassan as a director, thereby increasing the number of directors to six.”
Cocrystal Pharma, Inc. Form 8-K, filed April 24, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at BridgeBio Pharma, Inc.

Other people whose current roles at this company are on record from its filings.

Leadership on record at Cocrystal Pharma, Inc.

Other people whose current roles at this company are on record from its filings.

Leadership on record at EyePoint, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.